TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02422212

Intervention type: OTHER
Group type: OTHER
Intervention: patients eat a mixed solid meal
Description: The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients eat a mixed solid meal
Description: The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients eat a mixed solid meal
Description: The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
Study: NCT00961220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Applied topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-Benzylguanine
Description: Given IV
Study: NCT03027986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postural rehabilitation program
Description: This program is based on sensory-motor control
Study: NCT04267874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of nasal swabs, blood, urine, and stool

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of nasal swabs, blood, urine, and stool

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given black raspberry nectar PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given black raspberry nectar PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05860075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 will be administered once a week for 4 weeks.
Study: NCT02395926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline CR 600mg
Description: HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliatilin 400mg
Description: Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline CR 600mg
Description: HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
Study: NCT00282334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedical blood pressure monitoring
Description: Measurement of home blood pressure, three times per week for three months and once a week for three months.
Study: NCT02319421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alarm Reduction Script
Description: The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
Study: NCT03362970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFire Gastrointestinal Panel FilmArray®
Description: The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in \~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
Study: NCT03666832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: TEW-7197 1cycle 14days~-intake 5days, rest 2days
Study: NCT05752253

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling
Description: Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
Study: NCT02728830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV
Study: NCT02826642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH305
Study: NCT01148199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expandable metalic stent
Description: Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple plastic stents
Description: Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
Study: NCT01803984

Intervention type: DEVICE
Intervention: MRI

Intervention type: DEVICE
Intervention: MRI

Intervention type: DEVICE
Intervention: EndoPAT
Description: The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device

Intervention type: DEVICE
Intervention: EndoPAT
Description: The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device

Intervention type: OTHER
Intervention: Neuropsychological battery
Description: The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).

Intervention type: OTHER
Intervention: Neuropsychological battery
Description: The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Study: NCT03009214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMC303
Description: AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
Study: NCT04723121

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urine ELISA for immunological markers (IL-2 and IL-10)
Description: IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis
Description: blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control
Study: NCT03930719

Intervention type: DIAGNOSTIC_TEST
Intervention: Stroke screening tools
Description: Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stroke screening tools
Description: Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard.
Study: NCT01592357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks.
Study: NCT01916954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-day artemether-lumefantrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day artemether-lumefantrine
Study: NCT02592798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept IV administered on Day 1, 15, 29 and then every 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline administer on Day 1, 15, 29 and then every 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D5W
Description: Dextrose 5% in Water (D5W) administered on Day 1, 15, 29 and then every 28 days
Study: NCT02379663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban was taken orally in a dosage of 10mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin was injected subcutaneously in a dosage of 40mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: subcutaneous injection of 1 cc of normal saline once daily
Study: NCT04204889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaloacetic Acid
Description: The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.
Study: NCT02233517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning.
Study: NCT00942604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEP005 (ingenol mebutate) Gel
Description: two day treatment
Study: NCT01144663

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate®
Description: 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-CTM
Description: 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: 4-dose intramuscular injection
Study: NCT00942604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: two day treatment
Study: NCT02725918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2,iv,d1,q3w,until PD
Study: NCT01144663

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: 4-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: 4-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: 4-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: 4-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: 4-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: 4-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: 4-dose intramuscular injection
Study: NCT02725918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2,iv,d1,q3w,until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2,iv,d1,q3w,×4 cycles
Study: NCT04601961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as SEVO group. Induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.~Target controlled infusion (TCI) with a modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia and titrated to effect. The usual effect site concentration is 1.5-3 mcg.ml-1 and BIS monitoring will also be used to produce a value of between 40-60. As with patients in the SEVO group, remifentanil will be infused at a rate of between 0.1-0.3 mcg.kg.min-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
Study: NCT03773276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine boluses
Description: On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses.
Study: NCT02902237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tTF-NGR
Description: tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
Study: NCT01327482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
Study: NCT02187042

Intervention type: OTHER
Intervention: Best supportive care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
Study: NCT03641586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-283
Study: NCT02187042

Intervention type: OTHER
Intervention: call center
Description: Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
Study: NCT03164395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Cardioversion
Description: Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Cardioversion
Description: External Cardioversion per institutional protocol
Study: NCT01399164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 14C-B12 fortified bread
Description: A single serving of 14C-B12 fortified bread
Study: NCT02824900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration stimuli to neck muscles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration stimuli to hand

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Study: NCT03832465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin film-coated tablet
Description: 50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin intravenous solution
Description: 50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution.
Study: NCT02837965

Intervention type: DRUG
Intervention: treatment with topical superpotent corticosteroid therapy

Intervention type: DRUG
Intervention: treatment with systemic therapy (methotrexate)

Intervention type: DRUG
Intervention: treatment systemic therapy (prednisone)

Intervention type: DRUG
Intervention: treatment with systemic therapy (prednisone)

Intervention type: DRUG
Intervention: treatment with systemic therapy (doxycycline)
Study: NCT02073630

Intervention type: OTHER
Group type: OTHER
Intervention: active cerebellar stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: active cerebellar stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: sham cerebellar stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: sham cerebellar stimulation
Study: NCT03504111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Needle Tenotomy
Description: A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided needle tenontomy with be performed at the common extensor tendon at the area of tendinosis. There will be approximately 25 passes through the tendon with an 18 gauge needle. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided injection of the PRP will be performed at the common extensor tendon at the area of tendinosis. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia to the local skin